Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
Total Valuation
Aldeyra Therapeutics has a market cap or net worth of $303.82M. The enterprise value is ―.
Market Cap$303.82M
Enterprise Value―
Share Statistics
Aldeyra Therapeutics has 60,162,773 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60,162,773
Owned by Insiders12.93%
Owned by Institutions29.54%
Financial Efficiency
Aldeyra Therapeutics’s return on equity (ROE) is -0.79 and return on invested capital (ROIC) is -69.65%.
Return on Equity (ROE)-0.79
Return on Assets (ROA)-0.53
Return on Invested Capital (ROIC)-69.65%
Return on Capital Employed (ROCE)-0.70
Revenue Per Employee0.00
Profits Per Employee-6.21M
Employee Count9
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aldeyra Therapeutics is ―. Aldeyra Therapeutics’s PEG ratio is -0.11.
PE Ratio―
PS Ratio0.00
PB Ratio4.18
Price to Fair Value4.18
Price to FCF-6.87
Price to Operating Cash Flow-7.11
PEG Ratio-0.11
Income Statement
In the last 12 months, Aldeyra Therapeutics had revenue of 0.00 and earned -55.85M in profits. Earnings per share was -0.94.
Revenue0.00
Gross Profit0.00
Operating Income-60.12M
Pretax Income-55.85M
Net Income-55.85M
EBITDA-53.68M
Earnings Per Share (EPS)-0.94
Cash Flow
In the last 12 months, operating cash flow was -40.08M and capital expenditures -4.00, giving a free cash flow of -40.08M billion.
Operating Cash Flow-40.08M
Free Cash Flow-40.08M
Free Cash Flow per Share-0.67
Dividends & Yields
Aldeyra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.34
52-Week Price Change0.60%
50-Day Moving Average5.07
200-Day Moving Average4.48
Relative Strength Index (RSI)50.75
Average Volume (3m)1.33M
Important Dates
Aldeyra Therapeutics upcoming earnings date is Apr 30, 2026, Before Open (Confirmed).
Last Earnings DateMay 6, 2025
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
Aldeyra Therapeutics as a current ratio of 5.59, with Debt / Equity ratio of 28.14%
Current Ratio5.59
Quick Ratio5.59
Debt to Market Cap0.05
Net Debt to EBITDA0.73
Interest Coverage Ratio-31.21
Taxes
In the past 12 months, Aldeyra Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aldeyra Therapeutics EV to EBITDA ratio is -4.80, with an EV/FCF ratio of -5.96.
EV to Sales0.00
EV to EBITDA-4.80
EV to Free Cash Flow-5.96
EV to Operating Cash Flow-5.96
Balance Sheet
Aldeyra Therapeutics has $75.30M in cash and marketable securities with $15.54M in debt, giving a net cash position of $59.75M billion.
Cash & Marketable Securities$75.30M
Total Debt$15.54M
Net Cash$59.75M
Net Cash Per Share$0.99
Tangible Book Value Per Share$1.19
Margins
Gross margin is -26.14%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-26.14%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aldeyra Therapeutics is $8.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.67
Price Target Upside71.68% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast4.23%